Humacyte, Inc.
HUMADrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Aug 10, 2026
6dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
HUMA Earnings Report
EPS Est: $-0.10 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How HUMA's past catalysts played out
Human Acellular Vessel (HAV)
Renal Failure
Acellular Tissue Engineered Vessel (ATEV)
End Stage Renal Disease (ESRD)
HAV
Renal Failure
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Human Acellular Vessel (HAV) | Phase 3 | Renal Failure | - | - |
Acellular Tissue Engineered Vessel (ATEV) | Phase 3 | End Stage Renal Disease (ESRD) | - | - |
HAV | Phase 2 | Renal Failure | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Humacyte, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Humacyte, Inc.'s (HUMA) pipeline across Phase 3, Phase 2. Its lead program is Human Acellular Vessel (HAV) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Humacyte, Inc.'s next FDA catalyst?→
Humacyte, Inc.'s (HUMA) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HUMA biotech catalysts?→
Add HUMA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Humacyte, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.